fluorescent probes
16 January 2024
We are very proud to present our last paper in collaboration with the Institute of Neuroscience of the Universitat de Barcelona, the CiQUS – Center for Research in […]
18 October 2023
Sigma (σ) receptor subtypes, σ1 and σ2, are targets of wide pharmaceutical interest. σ1 receptor ligands are under evaluation in clinical trials for the treatment of diseases such as […]
19 July 2023
Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023
Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
7 March 2023
A different way to monitor GPCR binding, target engagement and internalization with a new fluorescent-conjugate toolbox. The past decade has witnessed fluorescently tagged drug molecules gaining […]
3 March 2023
Our portfolio of #GPCR#fluorescent ligands is growingWe have just added to our catalogue more fluorescent ligands for the C5a receptor, CELT-58 and CELT-68. The C5a anaphylatoxin chemotactic receptor 1 (C5aR, also […]
26 January 2023
Custom synthesis service for fluorescent ligands Celtarys provides custom chemical development services, specifically for the identification of a broad range of robust and complex fluorescent ligands […]
6 April 2022
The glucagon-like peptide-1 receptor (GLP1R), expressed in peripheral tissues and brain, is known to be involved in several metabolic and inflammatory processes. Despite its clear interest […]
3 February 2022
The group led by Dr. Eddy Sotelo at the University of Santiago de Compostela, in collaboration with the Uppsala University, has published a new article exploring […]